TA-02

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的 p38 MAPK 抑制剂，IC50 为 20 nM。

A potent p38 MAPK inhibitor with IC50 of 20 nM; inhibits the phosphorylation of proteins downstream of p38α MAPK such as MAPKAPK2 and HSP27 during cardiogenesis, and increases ATF-2 and MEF2C during cardiac differentiation.(In Vitro):TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such as MAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C ?expression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro.

TA-02 (5 μM) inhibits the phosphorylation of proteins downstream of p38α MAPK such as MAPKAPK2 and HSP27 during cardiogenesis. TA-02 at 5 μM concentration induces cardiogenesis, but also increases ATF-2 phosphorylation and MEF2C ?expression in contrast to what would be expected with a mechanism dependent on p38α MAPK inhibition.TA-02 induces T/Brachyury whereas SB203580 addition increased MESP1 and T/Brachyury transcripts.TA-02 significantly induces high NKX2-5 expression when applied between days 0-8.TA-02 is found to inhibit multiple targets with similar potency to p38α MAPK, such as p38α, p38β, JNK3, JNK2, CIT, CK1ε, DMPK2, JNK1, DDR1 CK1δ, MEK5, and ERBB2.TA-02 and SB203580 reduce the nuclear TCF/LEF-1 driven transcription of luciferase similar to DKK-1.TA-02 (5 nM-5 μM) inhibits p38 and increases the anti-inflammation effects of BDNF on inflammation in vitro. Western Blot Analysis Cell Line:The nerve cell line AGE1.HN.Concentration:5 nM-5 μM.Incubation Time:44 h (100 ng/ml LPS for 4 h at 37°C).Result:Suppressed p-38 protein expression, reduced IL-1β, IL-6, IL-18 and TNF-α levels and inhibited iNOS and COX-2 levels in an in vitro model of SCI by BDNF overexpression, compared with the BDNF overexpression group.

——

TA02 | TA 02

MAPK/ERK Signaling

p38 MAPK

p38MAPK

Other Indications

——

1784751-19-4

333.3341

C20H13F2N3

>98% (HPLC)

10 mM in DMSO

FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=CC=C4F)=N2)C=C1

Pyridine, 4-[2-(2-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-

(-20℃)

With Ice Pack

≥ 2 years